BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology.
Ontology highlight
ABSTRACT: Lithium is first-line therapy for bipolar affective disorder and has recently been shown to have protective effects in populations at risk for Alzheimer's disease (AD). However, the mechanism underlying this protection is poorly understood and consequently limits its possible therapeutic application in AD. Moreover, conventional lithium formulations have a narrow therapeutic window and are associated with a severe side effect profile. Here we evaluated a novel microdose formulation of lithium, coded NP03, in a well-characterized rat model of progressive AD-like amyloid pathology. This formulation allows microdose lithium delivery to the brain in the absence of negative side effects. We found that NP03 rescued key initiating components of AD pathology, including inactivating GSK-3β, reducin
SUBMITTER: Wilson EN
PROVIDER: S-EPMC5611736 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA